Latest Breaking News On - Institute of nuclear medicine - Page 13 : vimarsana.com

DRDO 2G drug repurposed medicine not new ICMR statement

India's first indigenous anti-COVID drug 2-DG is a 'repurposed' medicine, the Indian Council of Medical Research said on Thursday. According to ICMR DG Dr. Balram Bhargava, the drug was earlier used for cancer treatment.

"2DG will be of immense benefit to the people suffering from COVID19"

DRDO's anti-COVID-19 drug 2-DG likely to be available by mid-June: Dr Reddy's | India News

Explainer: All About DRDO's New COVID Drug

JD-S plans to distribute DRDO's anti-Covid drug to K'taka's people

As Karnataka battles the second wave of Covid, Janata Dal-S leader H.D. Kumaraswamy on Tuesday said that the party was mulling buying stocks of the indigenously developed anti-Covid drug to distribute among the state's people.

DRDO's 2-DG anti-Covid drug to be available by mid June: Dr Reddy's | India News

NEW DELHI: Dr Reddy's on Wednesday said that the supply of anti-Covid drug 2-deoxy-D-glucose (2-DG) developed by the Defence Research and Development Organisation (DRDO) is expected to commence in mid-June. In a statement, Hyderabad based Dr Reddy's said that the drug has not been launched in the market yet and people should be cautious of agents selling spurious or illegal products in the name of 2DG. The anti-Covid therapeutic application of the drug has been developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a leading laboratory of the DRDO, in collaboration with Dr Reddy's Laboratories (DRL) in Hyderabad.

DRDO's 2-DG anti-Covid drug to be available by mid-June: Dr Reddy's | India News

India News: Dr Reddy's on Wednesday said that the supply of anti-Covid drug 2-deoxy-D-glucose (2-DG) developed by the Defence Research and Development Organisati

COVID-19: Commercial launch and supply of DRDO's 2DG drug expected to commence in mid-June

COVID-19: Commercial launch and supply of DRDO's 2DG drug expected to commence in mid-June File Image The Drugs Controller General of India that approved oral drug 2-deoxy-D-glucose (2-DG) developed by the DRDO for emergency usage to treat the COVID-19 infection was released by Defence Minister Rajnath Singh and Union Health Minister Dr Harsh Vardhan on May 17. The drug has been developed by DRDO's Institute of Nuclear Medicine and Allied Sciences (INMAS) in collaboration with Dr Reddy's Laboratories. DRDO Chairman Dr G Satheesh Reddy told ANI that DRDO and Dr Reddy's lab had gone through the complete trials and conducted trials across 30 hospitals and on a large number of patients.

DRDO's 2-DG was Found to be Safe in COVID-19 Patients: Govt

DRDO's 2-DG was Found to be Safe in COVID-19 Patients: Govt The patients treated with 2-DG showed faster symptomatic cure than Standard of Care (SoC) on various endpoints   |  18 May 2021 8:07 AM GMT New Delhi: Defence Minister Rajnath Singh and Health Minister Dr Harsh Vardhan on Monday released the first batch of the developed anti- COVID-19 drug, 2-deoxy-D-glucose (2-DG). Drugs Controller General of India (DCGI), the national drug regulator, had cleared the formulation on May 1 for emergency use as an adjunct therapy in moderate to severe COVID-19 patients. The Ministry of Defence had said in a release earlier this month that 2-DG has been developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), New Delhi, a lab of the Defence Research and Development Organisation (DRDO), in collaboration with Dr Reddy's Laboratories.

Will examine data of 2-DG drug for adding it to national COVID treatment protocol: Govt

Send At a press conference, NITI Aayog member (health) Dr V K Paul said the Drugs Controller General of India (DCGI) has granted permission for emergency use of the drug after looking at the data. Representative Image: PTI New Delhi: The government will consider including India's first indigenous anti-COVID drug 2-DG in the national COVID-19 treatment protocol after examining the data of the medicine, officials said Tuesday. At a press conference, NITI Aayog member (health) Dr V K Paul said the Drugs Controller General of India (DCGI) has granted permission for emergency use of the drug after looking at the data.